Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Bristol-Myers Squibb
Novartis
Kivu Bioscience Inc.
Genentech, Inc.
AstraZeneca
Boehringer Ingelheim
Boehringer Ingelheim
AbbVie
Eli Lilly and Company
Johnson & Johnson Enterprise Innovation Inc.
OncoC4, Inc.
Exscientia AI Limited
USWM, LLC (dba US WorldMeds)
Seagen Inc.
Seagen Inc.
KaliVir Immunotherapeutics
Pfizer
Pfizer
Fate Therapeutics
Conjupro Biotherapeutics, Inc.
AstraZeneca
Zumutor Biologics Inc.
Pfizer
Arcus Biosciences, Inc.
IDEAYA Biosciences
Sotio Biotech Inc.
Pfizer
Pfizer
Erasca, Inc.
EMD Serono
EpiBiologics
Eli Lilly and Company
GlaxoSmithKline
Pfizer
Bayer
Coherus Oncology, Inc.
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
Exelixis
Aktis Oncology, Inc.
ViroMissile, Inc.
Erasca, Inc.
R-Pharm
Radiopharm Theranostics, Ltd
Seagen Inc.
Pfizer
AstraZeneca
Pfizer
Tizona Therapeutics, Inc